Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Massive study checks if PCV20 vaccine stops pneumonia in At-Risk adults

NCT ID NCT07251465

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 26, 2026 · Updated 3 times

Summary

This study looks at health records of over 800,000 adults to see if the PCV20 vaccine reduces pneumonia cases. Researchers will compare pneumonia rates in people who got the vaccine versus those who did not. The goal is to measure how effective PCV20 is in adults aged 18 and older with conditions that raise their risk for pneumococcal disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PCV20 vaccine
What this could lead to
If effective, this could confirm that PCV20 helps prevent pneumonia in adults with higher risk, supporting its wider use.
What could go wrong
This is an observational study using existing records, not a controlled trial. Results may be affected by unmeasured differences between vaccinated and unvaccinated groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

846,279 people

The number who actually took part.

Started

Jan 2026

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study will include a cohort of adults 19-64 years of age with at least one medical or behavioral risk factor associated with an increased risk of pneumococcal disease and a cohort of adults ≥65 years of age. Individuals who meet the eligibility criteria as of 01 July 2022 or who become eligible during the cohort identification period (01 July 2022 through 31 May 2025) will be included in the study. Individuals could contribute to both the 19-64 and ≥65 years of age cohorts if the individual met the inclusion and exclusion criteria for each respective cohort. Follow-up time will be classified by PCV20 exposure status. Within each cohort (19-64, ≥65 years), individuals can contribute one PCV20-unvaccinated time-segment, one PCV20-vaccinated time-segment, or both.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 19-64 years of age cohort 1. Aged ≥19 at some point between July 1, 2022 and May 31, 2025 with 1-year continuous membership prior to July 1, 2022 2. At least 1 year of continuous enrollment as a KPSC member prior to the index date, allowing for 45-day administrative gaps 3. Age 19-64 years of age on the index date with ≥1 medical condition or risk factor identified during the 1-year continuous enrollment period prior to the index date 4. At least one outpatient visit prior to the index date * 65 years cohort 1. Aged ≥19 at some point between July 1, 2022 and May 31, 2025 with 1-year continuous membership prior to July 1, 2022 2. ≥1 year of continuous enrollment as a KPSC member prior to the index date, allowing for 45-day administrative gaps 3. Age ≥65 years on the index date 4. At least one outpatient visit prior to the index date Exclusion Criteria: 19-64 years of age cohort <!-- --> 1. Received PCV20 prior to June 1, 2022, turning age 19 years, or meeting the medical condition or behavioral risk factor inclusion criteria 2. Vaccinated index date is \>30 days after the first PCV20 vaccination date or \>1 dose of PCV20 is received \<30 days prior to the index date 3. Received PCV15 or PCV21 prior to the index date 4. Received PPSV23 ≤2 years prior to the index date 5. Received PCV13 ≤5 years prior to the index date 6. Outcome-related diagnosis code in the EHR \<30 days prior to the index date * 65 years cohort 1. Received PCV20 prior to June 1, 2022 or prior to turning ≥65 years of age 2. Vaccinated index date is \>30 days after the first PCV20 vaccination date or \>1 dose of PCV20 is received \<30 days prior to the index date 3. Received PCV15 or PCV21 prior to the index date 4. Received PPSV23 ≤2 years prior to the index date 5. Received PCV13 ≤5 years prior to the index date 6. Outcome-related diagnosis code in the EHR \<30 days prior to the index date

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Community acquired pneumonia (CAP) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Pfizer

    New York, New York, 10001, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.